INFECTION AND DRUG RESISTANCE, cilt.10, ss.393-399, 2017 (SCI-Expanded)
Background: The rise in community-acquired urinary tract infections (UTIs) with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains raises the question of how to treat these infections effectively in pediatric outpatients. Amikacin has shown promising in vitro activity against ESBL-producing urinary isolates of E. coli; however, clinical data are limited.